Uflex is an integrated packaging company producing films (BOPP, BOPET, PET chips) and downstream packaging solutions including aseptic liquid packaging, flexible laminates, and woven polypropylene bags. It operates across India, Americas, Europe, Middle East and Africa, with India contributing about 44% of revenue and overseas 56%. The company is the market leader in aseptic liquid packaging in India, a niche with few global players, while its packaging films business faces intense import competition. In Q1 FY27, reported EBITDA margin reached 17%, up 480 bps year-on-year, while FY26 full-year margin was 12.8%, reflecting the improving mix. The business earns its economics from the aseptic and specialty film segments, which carry higher barriers and pricing power, while commodity films remain a scale game.
The persistence of these economics rests on integration and qualification cycles. Uflex is backward integrated from PET chips to films to finished packaging, which ensures supply reliability and cost control. Aseptic packaging requires food-safety certifications and long customer qualification processes, creating high switching costs; customers are willing to pay a premium for local sourcing and security of supply, as seen in the Middle East and Africa where volumes grew 14.9% year-on-year in Q1 FY27. The recycling plant, commissioned in April 2026, holds USFDA approval and food-grade licenses that are scarce, while the WPP facility in Mexico targets the North American pet food market with margins expected to be much higher than the company average. However, the films segment is commoditized, with BOPET overcapacity expected to persist for two years and low-priced imports pressuring Europe and India.
The inflection is now. Three major projects are coming online in FY27: the 12 billion pack aseptic plant in Egypt (commissioned in H1 FY27), the 80 million unit WPP plant in Mexico (commissioned July 2026), and the 39,600 MT recycling plant (commissioned April 2026). Management guides FY27 aseptic sales volume of 10.5 billion packs, up from 7.97 billion in FY26, and expects FY27 revenue growth of 35% with similar EBITDA growth, followed by another 30%+ growth in FY28. By mid-2028, the company should have these capacities ramped: Egypt aseptic targeting 30% utilization in the first year, improving thereafter, and the Dharwad BOPP line (54,000 MTPA) commissioned during FY27-28. The incremental revenue from the three new projects alone is estimated at Rs 2,000-2,500 crore at full capacity with high-teens margins, which would lift the overall EBITDA margin from 12.8% in FY26 to the mid-to-high teens.
Management's track record has been mixed, but the latest call shows a clear improvement. In FY26, guidance was downgraded twice: revenue growth cut from 10% to 5% and EBITDA from Rs 2,000-2,100 crore to Rs 1,800-1,850 crore, citing tariffs and import surges. Capex timelines slipped, with the India aseptic expansion moving from January 2025 to October 2025, and Egypt/Mexico projects pushed to Q1 FY27. However, the August 2026 call reported Q1 FY27 EBITDA margin of 17% (normalized 15.5%), debt-to-EBITDA reduced from 4.5x to 3.5x, and interest cost down 0.3-0.4% with a target of 1% reduction in a year. Management now guides FY27 revenue and EBITDA growth of 35%, and debt-to-EBITDA below 3x by FY28, a significant upgrade from prior expectations. The company also expects to capitalize Rs 1,900-2,000 crore of CWIP in FY27, indicating the new assets are becoming operational.
The earnings path is visible: if FY26 EBITDA was around Rs 1,800-1,850 crore, a 35% growth implies FY27 EBITDA of roughly Rs 2,430-2,500 crore, and similar growth in FY28 would push it above Rs 3,200 crore. This would bring net debt (currently around Rs 7,750 crore) down to below 3x EBITDA, assuming no major additional borrowings. The key assumptions are that the Egypt aseptic plant ramps as planned, the WPP and recycling plants achieve targeted utilization, and film margins stabilize despite import pressure. The single most important watchpoint is the Egypt plant's first-year utilization, which management itself flags at 30% due to technical challenges; any delay or underperformance there would directly hit the FY27 volume guidance of 10.5 billion packs. Additionally, duty-free imports from Indonesia into India and low-priced imports in Europe could compress film margins, but the shift toward value-added films (metallized, ultra-high barrier) with current utilization of only 30-40% provides headroom. The tension between past execution misses and current strong results is resolved by the fact that the new capacities are now commissioned and contributing, making the 18-24 month outlook a story of operating leverage and deleveraging.
companyname: UFLEX Limited ticker: UFLEX sector: Flexible Packaging and Solutions UFLEX Limited is India's largest multinational flexible packaging and solutions company, with an integrated presence across the entire packaging value chain. The company operates 23 manufacturing facilities across nine countries, serving customers in more than 150 countries. Its global workforce exceeds 16,000 people, including over 12,000 permanent employees (Annual Report FY26). The integration model is the cor...
Read the full report →capex, margin expansion, new product segment, geographic expansion
FY27 aseptic packaging sales volume guided at 10.5 billion packs driven by Egypt plant commissioning and improved utilization
Guidance upgradedmixed
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Uflex Limited and 4,900+ companies.
5-day free pass. No card required.